ArticleCureus2025
Partial Left Main Coronary Artery Obstruction Due to Migration of a Bioprosthetic Aortic Valve 60 Days After Transcatheter Aortic Valve Replacement: A Rare Clinical Case.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter aortic valve replacement (TAVR) offers a less invasive treatment alternative to surgical aortic valve replacement for high-risk patients. Although the procedure can be performed at low risk, life-threatening complications may arise in single cases during or even months after the procedure. Coronary obstruction has long been recognized as a potential complication of TAVR and is generally understood to occur within seconds or minutes after valve deployment. However, a few case reports have described the development of delayed coronary obstruction (DCO) occurring in the hours and days following the procedure. This is a case report of an 81-year-old patient who underwent TAVR due to aortic stenosis. The high implantation of a self-expandable valve, considered acceptable at the time of implantation, was eventually associated with severe myocardial ischemia that became clinically evident almost two months later. The patient underwent TAVR successfully, although the final aortogram revealed a somewhat high implant position. However, 50 days after the implantation, the patient started complaining of daily episodes of angina, dyspnea, and hypotension. She was admitted to the hospital 10 days later, and that day she developed a similar angina episode, followed by pulmonary edema and cardiogenic shock. The patient rapidly improved with intravenous vasoconstrictors and stabilized with the use of an intra-aortic balloon pump. A transthoracic echocardiogram (TTE) revealed a well-functioning prosthetic valve. An aortic root angiogram revealed patent coronary arteries. However, the non-coronary sinus of Valsalva (SOV) was barely opacified, and the left SOV was filling through a slit as a result of a prosthetic valve that had gradually migrated upwards in the sinotubular junction (STJ). This, in turn, resulted in compromised blood flow to the left main (LM) coronary artery ostium. The obstruction was gradually worsening over time, leading to myocardial ischemia and cardiogenic shock. An attempt was made to treat this condition interventionally by trying to cross into the left SOV and catheterize the LM ostium with the intention of percutaneous coronary intervention (PCI) treatment, but it was not successful. After these failed attempts, the decision was made to proceed with a bypass graft implantation to the left anterior descending artery, with off-pump surgery. Regrettably, the patient did not survive the operation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.